1201709115_133b3927a3_b

Bayer and Exscientia to work together on AI in cardiovascular and oncology drug discovery

pharmafile | January 10, 2020 | News story | Medical Communications Bayer, Exscientia, oncology 

Bayer AG has partnered with Exscientia to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG’s Pharmaceuticals Division and Head of Research and Development, said: “The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures.”

Exscientia, a leading AI drug discovery company, will apply its Centaur Chemist AI drug discovery platform to discover and optimise drug candidates. Exscientia will initially work on three projects, with the targets agreed between them and Bayer.

Exescientia may be eligible to receive €240 million. This could include research payments and sales royalties.

Professor Andrew Hopkins, Chief Executive Officer of Exscientia, said: “We’re delighted to collaborate with Bayer, a globally recognised pharmaceutical company. Since our pioneering Nature papers demonstrating the automated design of small molecules, we have enhanced our platform and exemplified it commercially, by accelerating the discovery of future drug molecules with partners.” 

Conor Kavanagh

 

Related Content

Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment

Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

Galapagos and BridGene Biosciences enter collaboration for oncology drug discovery

Galapagos NV and BridGene Biosciences have announced that they have entered into a strategic collaboration …

Latest content